I am a drug discovery and development scientist seeking to deliver the best therapies for patients with debilitating diseases. My expertise include 16 years of project design, management, data analysis, interpretation and development of drugs for various diseases. I am a driven, resourceful individual who maintains a positive, proactive attitude when faced with adversity. Currently, I am seeking employment opportunities that will allow me to use my diverse skill set to develop and promote treatments that benefit human health. Specific fields of interest include drug discovery and clinical development.
Bachelor of Science: Biology and ChemistryBaylor University － Waco, TXBiology and Chemistry
01/2013 to 10/2016
Scientist IINovartis Institutes of Biomedical Research NIBR Ophthalmology Glaucoma and Ocular Regenerative Medicine Research － Cambridge, MA
Glaucoma Research Unit Set up pharmacology models in rodents to model human Glaucoma as a tool to evaluate novel treatments.
Main stakeholders included management, medicinal chemistry, gene therapy team, DMPK, pharmaceutical discovery, preclinical/clinical development and intellectual property.
Principal role involved working in a collaborative manner with our in-vivo research team to coordinate and execute yearly objectives of novel compound evaluation in normotensive intraocular pressure models and create Glaucoma disease models using gene therapy viral vectors.
To date, I designed study protocols and completed approximately 25 in-vivo studies.
I made a significant observation that led to the confirmation of a gene thought to have a role in the development of Glaucoma.
I verified the function of this gene by using viral vectors to modulate the gene's function in rodents.
I established a published system to accurately measure intraocular pressure (IOP) in rodents over period of time.
This resulted in higher confidence in data collected from non-invasive measurement techniques.
We now use this system at the conclusion of every non-invasive IOP study to confirm results.
Collaborated with imaging scientists to improve throughput, quality and automation of ocular histology samples.
This led to the approximate increase of 15% in overall efficiencies and deliverables.
Ocular Regenerative Medicine Research Unit: Inaugurated in-vitro and in-vivo pharmacology models to evaluate novel regenerative medicine approaches for the treatment of corneal diseases such as limbal corneal epithelial stem cell deficiency and corneal endothelial dystrophy.
Main stakeholders included management, external collaborators, pharmaceutical discovery, preclinical/clinical development and intellectual property.
Primary responsibilities included establishing methods to isolate cells from human donor corneas and establish primary human corneal endothelial cell cultures to characterize mechanisms of regeneration, disease and evaluate new therapies.
Developed a mouse model of limbal stem cell deficiency to evaluate treatments in preclinical trials.
Other Roles and Functions: Member of NIBR's in-vivo community councils to ensure adherence to human and ethical handling of rodents.
Member of Ophthalmology Health and Safety Committee to ensure safety compliance by all associates.
This led to the fewest number of safety related incidents during my tenure.
01/2008 to 01/2013
01/2004 to 01/2008
01/2003 to 01/2013
OphthalmologyLEXICON PHARMACEUTICALS, INC － The Woodlands, TX
01/2003 to 01/2004
Principal Research Associate
Established and managed research teams of highly motivated scientists to create a multi-disciplinary environment to explore fundamental questions in vision research coupled with the expertise to help turn innovations into medical treatments.
Disease areas included diabetic retinopathy, wet age-related macular degeneration (wet-AMD), retinal degeneration, uveitis and dry eye.
Main stakeholders included senior management, external collaborators, pharmaceutical discovery, medicinal chemistry, DMPK, Toxicology/Pathology, pharmaceutical discovery/HTS, medicinal chemistry, preclinical/clinical development, intellectual property and business development at a pharmaceutical company of 300 people in the Houston area.
Primary responsibilities included the identification, evaluation, development and management of drug candidates for ocular diseases such as uveitis, dry eye, diabetic retinopathy and wet-age related macular degeneration.
Responsible for managing, directing and performing hypothesis based research on three small molecule research programs for the treatment of uveitis and ocular surface diseases.
As an ophthalmology therapeutic area lead, I worked with cross-functional teams with expertise in pharmaceutical discovery/HTS, medicinal chemistry, DMPK, preclinical/clinical development, intellectual property and business development to present research proposals, resourcing, budgets and scientific updates on a quarterly basis to senior management on each of our drug discovery programs.
Managed the discovery process of programs up to nomination of an IND candidate.
Identified several angiogenesis drug targets from Lexicon's mouse transgenic platform using several screening methodologies including implantation of a Developmental Biology program (ARVO 2008, Abstract#A448).
Developed, validated and conducted rodent pharmacology assays of ocular disease such as infectious and autoimmune uveitis, oxygen-induced retinopathy, laser-induced choroidal neovascularization, benzalkonium chloride-induced dry eye and genetic models to characterize mouse knockouts and prioritize lead molecules.
Managed relationships and collaborated with external CROs, academic investigators and KOLs to validate drug targets, ocular drug delivery formulations, conduct non-GLP pharmacokinetics/efficacy studies and toxicology as required.
Involved in the preparation and presentation of drug discovery programs to promote funding from large pharmaceutical companies and investors.
Supervised and work with research teams of research associates to prosecute preclinical drug development activities at a throughput of eight in-vivo studies per month.
Collaborated with both industry and academic scientists on targets relevant to ocular physiology leading to publications in peer-reviewed journals (references provided below).
Presented research at scientific and business meetings on multiple occasions (references provided below).
Management experience included all aspects of laboratory personnel recruitment, training, supervision, budget management, material and equipment acquisition and integration.
Reported to the Vice President of Ophthalmology and the Vice President of Immunology pharmaceutical research.
Skill sets: Induction of in-vivo pharmacology disease models and monitoring of physiological, biochemical and structural changes in the eye by histopathological, protein (western blot, ELISA or IHC) and mRNA analysis (qRT-PCR, in-situ hybridization).
Developmental biology skills include harvesting and dissecting mouse embryos for histological and immunohistochemical evaluation of blood vessel development.
Proficient in the use of RNA interference tools to evaluate gene function in angiogenesis assays including endothelial cell migration, proliferation and tubule formation in-vitro.
Preparation and cryosectioning of tissue for immunohistochemistry, immunofluorescence and confocal microscopy.
Proficient in preparing retinas, RPE-choroid-sclera whole mounts for immunohistochemistry, imaging and analysis.
Routinely perform enteral and parenteral dosing (e.g.
IP, SC, intravitreal, subretinal injections) and blood draws in rodents.
Experience using adenoviruses in mouse ocular disease models.
Implement novel imaging and analytical tools to expedite drug discovery while maintaining scientific quality (ARVO 2010, Abstract#A566).
Strong experience in using various image analysis tools such as Imaris, AngioSys, Image Pro, Aperio's image algorithm packages to assess morphological differences either in-vivo or in-vitro studies.
Perform analyses of ocular imaging using KOWA and Micron III fundus and fluorescein angiography systems.
Working knowledge of optical coherence tomography in rodents with Bioptigen Spectral Domain Imaging System.
01/2002 to 01/2003
Principle Research Associate
01/2001 to 01/2002
Senior Research Associate
01/2000 to 01/2003
LEXICON PHARMACEUTICALS, INC － THE WOODLANDS, TX
01/2000 to 01/2001
Responsible for generating genetically modified mice contributing to the company's goal of creating 4,650 novel gene deficient lines to identify novel drug targets for cardiovascular disease, metabolism, neurology, immunology, oncology and ophthalmology.
I participated in a 60-80 person department working closely with intellectual property, business development and external clients to achieve project milestones on stringent timelines.
Accomplished the generation of 25 projects on average per year.
Reduced completion of project timelines from 12 to 9 weeks per project.
Maintained accurate assessment of project data, deliverables and reports for internal and external clients.
Assisted pharmaceutical biology groups on special projects as needed to advance understanding of target biology.
Bassett EA, Tokarew N, Allemano EA, Mazerolle C, Morin K, Mears AJ, McNeill B, Ringuette R, Campbell C, Smiley S, Pokrajac NT, Dubuc AM, Ramaswamy V, Northcott PA, Remke M, Monnier PP, Potter D, Paes K, Kirkpatrick LL, Coker KJ, Rice DS, Perez-Iratxeta C, Taylor MD, Wallace VA. Norrin/Frizzled4 signaling in the preneoplastic niche blocks medulloblastoma initiation. Elife. 2016 Nov 8; 5. Carstens N, Williams S, Goolam S, Carmichael T, Cheung MS, Büchmann-Møller S, Sultan M, Staedtler F, Zou C, Swart P, Rice DS, Lacoste A, Paes K, Ramsay M. Novel mutation in the CHST6 gene causes macular corneal dystrophy in a black South African family. BMC Med Genet. 2016 Jul 20; 17(1):47. McNeill B, Mazerolle C, Bassett EA, Mears AJ, Ringuette R, Lagali P, Picketts DJ, Paes K, Rice D, Wallace VA. Hedgehog regulates Norrie disease protein to drive neural progenitor self-renewal. Hum Mol Genet. 2013 Mar 1; 22(5):1005-16. Paes K, Wang E, Henze K, Suwanichkul A, Kirkpatrick L, Vogel P, Potter D, Rice DS. Frizzled-4 is involved in retinal angiogenesis and the maintenance of the blood-retinal-barrier. Invest Ophthalmol Vis Sci. 2011 Aug 16; 52(9):6452-61. Paes K, Wang E, Henze K, Suwanichkul A, Kirkpatrick L, Vogel P, Potter D, Rice DS. Association of Research in Vision and Ophthalmology, ARVO Abstract#A222. May 2011-Frizzled-4 is involved in retinal angiogenesis and the maintenance of the blood-retinal-barrier. (ARVO Poster). Paes K, Wang E, Henze K, Suwanichkul A, Kirkpatrick L, Vogel P, Potter D, Rice DS. Association for Ocular pharmacology and Therapeutics, AOPT, 10th Scientific Meeting, February 2011. Frizzled-4 is involved in retinal angiogenesis and the maintenance of the blood-retinal-barrier. (AOPT Poster) Paes K, Wang E, Wudali R, Rice DS. Association of Research in Vision and Ophthalmology, ARVO Abstract#A566. May 2010. Evaluation of Alternative Methods to Quantify Ocular Angiogenesis in Mice. (ARVO Poster). Junge HJ, Yang S, Burton JB, Paes K, Shu X, French DM, Costa M, Rice DS, Ye W. TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling. Cell. 2009 Oct 16; 139(2):299-311. Rice DS, Paes K, Markesich D, Walke W, Zambrowicz B. Association of Research in Vision and Ophthalmology, ARVO Abstract#A448. May 2008. Identifying Mammalian Proteins That Modulate Angiogenesis in-vivo Using a Large Scale Genetic Screen. (ARVO Poster). Paes K, Utility of Digital Pathology in Ophthalmic Drug Discovery, presented at Pathology Visions 2007, San Diego, CA (Path Visions Presentation). Schmidt M, Paes K, De Mazière A, Smyczek T, Yang S, Gray A, French D, Kasman I, Klumperman J, Rice DS, Ye W. EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution. Development. 2007 Aug; 134(16):2913-23.
The Association for Research in Vision and Ophthalmology (ARVO)
The Association for Ocular Pharmacology and Therapeutics (AOPT)